Core Insights - Telix Pharmaceuticals Limited has announced a research collaboration with University Hospital Essen to explore the prognostic value of PSMA-PET imaging through artificial intelligence [1][4]. Group 1: Research Collaboration - The PROMISE-PET registry is a multi-center, prospective, observational study aimed at assessing the prognostic value of PSMA-PET imaging and comparing it with established clinical risk scores [2]. - The registry has been collecting data since 2018, standardizing PET readings from over 15,000 patients across more than 50 institutions globally [2]. Group 2: AI and Imaging Technology - The collaboration aims to develop AI-based prediction models for survival using gallium-68 (Ga)-PSMA-11-PET imaging data, leveraging Telix's automated machine learning platform [3]. - PSMA-PET imaging is now considered a standard of care in prostate cancer management, offering greater accuracy than conventional imaging methods [3]. Group 3: Expert Commentary - Wolfgang Fendler, MD, emphasized the importance of Telix's involvement in enhancing risk stratification and informing future clinical guidelines [4]. - Simon Wail from Telix highlighted the significance of accessing a large, standardized PSMA-PET dataset for developing clinically relevant prognostic models [4]. Group 4: Company Overview - Telix Pharmaceuticals is focused on developing therapeutic and diagnostic radiopharmaceuticals, with operations in multiple countries including the U.S., U.K., and Japan [5]. - The company has received approvals for its first-generation PSMA-PET imaging agent, Illuccix®, in various global markets [6].
Telix Joins Forces with University Hospital Essen on PROMISE-PET: Optimizing Patient Management through AI-enabled PSMA-PET Imaging